Dr. Agrawals Eye Hospital Intrinsic Value
Dr. Agrawals Eye Hospital intrinsic value. Dr. Agrawals Eye Hospital (DRAGARWQ) median intrinsic value is ₹2560.65 from 10 valuation models (range ₹1384–₹3939), vs current price ₹5995.50 — -57.3% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse DRAGARWQ FII DII holdings to track promoter, FII and institutional holdings.
DRAGARWQ Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Agrawals Eye Hospital intrinsic value across 10 models vs current price ₹5995.50 — upside/downside and value range per method. Browse DRAGARWQ annual financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3493.60 | ₹2794.88 - ₹4192.32 | -41.7% | EPS: ₹158.80, Sector P/E: 22x |
| Book Value Method | asset | ₹1384.00 | ₹1245.60 - ₹1522.40 | -76.9% | Book Value/Share: ₹692.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2016.00 | ₹1814.40 - ₹2217.60 | -66.4% | Revenue/Share: ₹1008.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3160.00 | ₹2844.00 - ₹3476.00 | -47.3% | EBITDA: ₹158.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3939.17 | ₹3151.34 - ₹4727.00 | -34.3% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2444.39 | ₹2199.95 - ₹2688.83 | -59.2% | EPS Growth: 19.2%, Fair P/E: 15.4x |
| Growth Adjusted P/E | growth | ₹2560.65 | ₹2304.59 - ₹2816.72 | -57.3% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹2997.75 | ₹2697.97 - ₹3297.53 | -50.0% | ROE: 22.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1798.65 | ₹1618.79 - ₹1978.52 | -70.0% | EPS: ₹158.80, BVPS: ₹692.00 |
| Dividend Yield Method | dividend | ₹1798.65 | ₹1618.79 - ₹1978.52 | -70.0% | DPS: ₹7.00, Target Yield: 2.5% |
DRAGARWQ Intrinsic Value vs Market Price — All Valuation Models
Dr. Agrawals Eye Hospital fair value range ₹1384–₹3939 vs current market price ₹5995.50 across 10 valuation models. For current market price and key ratios, visit DRAGARWQ share price screener.
DRAGARWQ Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Agrawals Eye Hospital median intrinsic value ₹2560.65, current price ₹5995.50 — Trading Above Calculated Value by 57.3%, margin of safety -100.0%.
What is the intrinsic value of DRAGARWQ?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Dr. Agrawals Eye Hospital (DRAGARWQ) is ₹2560.65 (median value). With the current market price of ₹5995.50, this represents a -57.3% variance from our estimated fair value.
The valuation range spans from ₹1384.00 to ₹3939.17, indicating ₹1384.00 - ₹3939.17.
Is DRAGARWQ undervalued or overvalued?
Based on our multi-method analysis, Dr. Agrawals Eye Hospital (DRAGARWQ) appears to be trading above calculated value by approximately 57.3%.
DRAGARWQ Financial Health — Key Ratios vs Industry Benchmarks
Dr. Agrawals Eye Hospital financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 22.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.66x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
DRAGARWQ Cash Flow Quality — Operating & Free Cash Flow
Dr. Agrawals Eye Hospital operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹145 Cr | ₹58 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹94 Cr | ₹28 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹90 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹70 Cr | ₹35 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹57 Cr | ₹34 Cr | Positive Free Cash Flow | 8/10 |